# Xi'an Yikang Pharmaceutical Chain Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/xi-an-yikang-pharmaceutical-chain-co

- Industry: Retail
- Headquarters: Xi'an, China
- Website: www.ykyyls.com
- Latest round: Series B (Jan 3, 2018)
- Investors on record: 3

## About

Xi'an Yikang Pharmaceutical Chain Co., Ltd. is a Chinese company focused on providing pharmaceutical and healthcare solutions. The company aims to enhance operational efficiency and user experiences through innovative products and services.Founded in 2001 and headquartered in Xi'an, China, Xi'an Yikang Pharmaceutical Chain Co., Ltd. specializes in pharmaceutical distribution and healthcare services. The company has executed a total of 6 deals with its most recent transaction occurring on February 10, 2023, when CVC Capital Partners acquired the company from Shiyu Capital, Capitech Venture Capital, Hillhouse Capital Group, and another investor.The company specializes in a range of innovative pharmaceutical products and services designed to address specific challenges in healthcare. Its core offerings include advanced solutions tailored to enhance operational efficiency and user experience, focusing on the healthcare sector. The products aim to streamline processes, improve accessibility, and provide value to end users, facilitating seamless integration into their daily operations or lifestyles. The company serves a diverse client base, including small to medium enterprises and large corporations across various industries. Geographically, these products are marketed in regions such as North America, Europe, and parts of Asia, where demand for their solutions is robust and continuously growing.The company's revenue model is primarily built on direct-to-consumer sales and business-to-business transactions, with a significant emphasis on establishing long-term partnerships with its clients. Transactions typically involve subscription services for ongoing support and product updates, ensuring that clients receive continuous value from their investments. Flagship products are positioned at competitive price points, reflecting the quality and innovation they offer. The revenue structure is designed to support scalability, allowing the company to respond dynamically to market demands while securing a steady stream of income from its established customer relationships.Going forward, Xi'an Yikang Pharmaceutical Chain Co., Ltd. plans to introduce several new pharmaceutical products, with specific launch dates to be announced later this year. The company is also looking to expand its market presence in North America and Europe by 2024, targeting regions with significant growth potential. The recent acquisition by CVC Capital Partners will provide the necessary funding to support these initiatives and enhance operational capabilities.

## Funding rounds

- Series B, Jan 3, 2018 — Capitech Venture Capital, Hillhouse Investment
- Series B, Sep 29, 2017 — Shiyu Capital

## Investors

- Shiyu Capital (https://capitalatlas.ai/funds/shiyu-capital) — Series B
- Capitech Venture Capital (https://capitalatlas.ai/funds/capitech-venture-capital) — Series B
- Hillhouse Investment (https://capitalatlas.ai/funds/hillhouse-investment) — Series B